Trials
9 active
13 in total · 11 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “Belimumab 200 mg/mL will be administered as SC injection in left or right thigh and the abdomen.”In the company’s words, NCT04179032 on ClinicalTrials.gov
- Tested for
- Systemic Lupus Erythematosus (2 trials), Lung Diseases, Interstitial, Connective Tissue Diseases, Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
- Main trialPhase 4
- “This is a prospective, open-label, single arm 3-year clinical study to describe the short-term and long-term efficacy and safety of belimumab in participants with autoantibody positive early SLE with ongoing disease activity despite stable first-line SLE therapy.”In the company’s words, NCT06411249 on ClinicalTrials.gov
- Other names
- BENLYSTA
Other drugs for Systemic Lupus Erythematosus
- CenerimodViatris Innovation GmbH · Phase 3
- IanalumabNovartis Pharmaceuticals · Phase 3
- UpadacitinibAbbVie · Phase 3
- QL1074Qilu Pharmaceutical · Phase 3
- Dapirolizumab pegolUCB Biopharma SRL · Phase 3
- Mycophenolate MofetilRoche · Phase 3
Coming up4
- 29 Jun 2027Phase 4 trial completes · ClinicalTrials.gov
- 30 Aug 2029Phase 3 trial completes · ClinicalTrials.gov
- 30 Aug 2029Phase 2/3 trial completes · ClinicalTrials.gov
- 27 Sep 2030Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials13
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Active, not recruiting | 29 Jun 2027 | A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) | |
| Phase 3Recruiting | 30 Aug 2029 | A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease | |
| Phase 3Recruiting | 27 Sep 2030 | A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE) | |
| Phase 2/3Recruiting | 30 Aug 2029 | A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease | |
| Phase 2Active, not recruiting | 16 Jan 2023 | Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE) | |
| Phase 4Completed | 18 Jun 2018 | Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE) | |
| Phase 3Completed | 25 Jul 2019 | Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis | |
| Phase 2/3Ended | not given | (Synbiose-2 )Synergetic B-cell immunomodulation in SLE – 2 nd study | |
| Phase 2Authorised | not given | BE-MOBILYZED: BElimumab to MOBIlise memory B-cells from secondary LYmhoid organs to improve memory B-cell HLA-specificity profiling to support delisting for transplant access in highly-sensitiZED. | |
| Phase 2Ended | not given | A phase II trial of belimumab in combination with rituximab/venetoclax in patients with refractory or relapsed chronic lymphocytic leukemia | |
| Phase 3Authorised | not given | RITUX-PLUS 2 : A phase 3 randomized and double-blind controlled trial comparing the efficacy and safety of rituximab combined with subcutaneous belimumab versus rituximab + placebo in adult patients with persistent or chronic immune thrombocytopenia (ITP) | |
| Phase 2Authorised | not given | TRIBECA - Multicenter randomized double-blind study comparing the efficacy and safety of belimumab in the treatment of non-infectious active cryoglobulinemia vasculitis compared to placebo TRIBECA STUDY (Treatment after RItuximab with BElimumab in mixed Cryoglobulinemia Associated vasculitis) | |
| Phase 4Authorised | not given | The effects of belimumab on synovial inflammation and composition of lymph nodes in SLE patients |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026